Mesoblast (MESO) Current Deferred Revenue (2015)
Mesoblast's (MESO) quarterly Current Deferred Revenue came in at $15.0 million in Q4 2015, down 33.33% quarter-over-quarter from $22.5 million in Q2 2015.
Mesoblast (MESO) Current Deferred Revenue (2015) Analysis & Trends
Mesoblast has disclosed Current Deferred Revenue across 1 years of filings, most recently posting $15.0 million for Q4 2015.
- Current Deferred Revenue for Q4 2015 came in at $15.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2015 was $15.0 million (changed N/A YoY), and the FY2015 annual result was $22.5 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $15.0 million for Q4 2015 at Mesoblast, down from $22.5 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $22.5 million in Q2 2015 to a low of $15.0 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 15.00 Mn |
| Jun 30, 2015 | 22.51 Mn |